HC Wainwright & Co. Reiterates Buy on scPharmaceuticals, Maintains $18 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on scPharmaceuticals (NASDAQ:SCPH) and maintained an $18 price target.
August 04, 2023 | 10:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
scPharmaceuticals (NASDAQ:SCPH) has had its 'Buy' rating reiterated and $18 price target maintained by HC Wainwright & Co.
The reiteration of a 'Buy' rating and maintenance of an $18 price target by HC Wainwright & Co. indicates a positive outlook for scPharmaceuticals. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100